

GLOBAL BIOENERGIES proceeds with a 100,000 euro draw down on its Standby Equity Distribution Agreement

Evry (France) – October 6th, 2014 – Global Bioenergies (Alternext Paris: ALGBE) carries out a new draw down on the equity line signed on May 16th, 2014 with Yorkville Advisors.

Global Bioenergies issues 2,600 new shares individually priced at 38.78 euros as part of this new draw down. As per the signed agreement, the issued price of these new shares includes a 5% discount on the lowest weighted average price of ordinary shares traded during the previous five consecutive trading days.

The funds will be distributed amongst the Company's programs.

The 2,600 new shares, which result in an equity dilution inferior to 0.1%, will be freely tradable on Alternext Paris and assimilated with the existing 2,757,156 shares.

About GLOBAL BIOENERGIES

Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the yield of its process and is actively entering the industrial pilot testing phase. The company recently replicated this success to propylene and butadiene and is also looking to continue with other members of the gaseous olefins family, key molecules at the heart of petrochemical industry. Global Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 – ALGBE)

Should you like to be kept informed, subscribe to our news feed on www.global-bioenergies.com

Follow us on Twitter: @GlobalBioenergi

Contact

GLOBAL BIOENERGIES

François-Henri Sahakian

Chief Financial Officer

Tel : + 33 (0) 1 64 98 20 50

Fax : +33 (0) 1 64 98 20 51

Email : invest@global-bioenergies.com



**Global Bioenergies
on video**

**ALGBE
LISTED
ALTERNEXT**